Coverage and/or Medical Necessity for the Use of Hyaluronan or Derivitive

by  Christine Woolstenhulme, QCC, QMCS, CPC, CMRS
February 2nd, 2017

Verify your local coverage determination and medical necessity requirements for the following codes:

Hyaluronate Polymers (L33432) - Noridian Medicare

J7320 - Hyaluronan or derivitive, genvisc 850, for intra-articular injection, 1 mg
J7321 - Hyaluronan or derivative, hyalgan or supartz, for intra-articular injection, per dose
J7322 - Hyaluronan or derivative, hymovis, for intra-articular injection, 1 mg
J7323 - Hyaluronan or derivative, euflexxa, for intra-articular injection, per dose
J7324 - Hyaluronan or derivative, orthovisc, for intra-articular injection, per dose
J7325 - Hyaluronan or derivative, synvisc or synvisc-one, for intra-articular injection, 1 mg
J7326 - Hyaluronan or derivative, gel-one, for intra-articular injection, per dose
J7327 - Hyaluronan or derivative, monovisc, for intra-articular injection, per dose
J7328 - Hyaluronan or derivative, gel-syn, for intra-articular injection, 0.1 mg

Medicare will cover the cost of the injection and the injected hyaluronate polymer for patients who meet the following clinical criteria:

The frequency of injections is:

An initial series of three to five weekly injections per knee. Note: Synvisc-One® and Gel-One® are administered through a single intra-articular injection.

A repeat series of injections for patients who have responded to the first series may be given individual consideration by Medicare for coverage under the following circumstances:

Drug Wastage

Medicare provides payment for the discarded drug/biological remaining in a single-use drug product after administering what is reasonable and necessary for the patient's condition. If the physician has made good faith efforts to minimize the unused portion of the drug/biological in how patients are scheduled and how he ordered, accepted, stored, and used the drug, and made good faith efforts to minimize the unused portion of the drug in how it is supplied, the program will cover the amount of drug discarded along with the amount administered.

Note: The JW modifier is not used on claims for drugs or biologicals provided under the Competitive Acquisition Program (CAP).

Coverage and/or Medical Necessity for the Use of Hyaluronan or Derivitive. (2017, February 2). Find-A-Code Articles. Retrieved from https://www.findacode.com/articles/coverage-and-or-medical-necessity-for-the-use-of-hyaluronan-or-derivitive-31572.html

© InnoviHealth Systems Inc

Article Tags  (click on a tag to see related articles)


Publish this Article on your Website, Blog or Newsletter

This article is available for publishing on websites, blogs, and newsletters. The article must be published in its entirety - all links must be active. If you would like to publish this article, please contact us and let us know where you will be publishing it. The easiest way to get the text of the article is to highlight and copy. Or use your browser's "View Source" option to capture the HTML formatted code.

If you would like a specific article written on a medical coding and billing topic, please Contact Us.


contact

innoviHealth Systems, Inc.
62 East 300 North
Spanish Fork, UT 84660
Phone: 801-770-4203 (9-5 Mountain)
Email:
free demo
request yours today
pricing
for any budget
sign IN
welcome back!

Thank you for choosing Find-A-Code, please Sign In to remove ads.